Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo's ...

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and ...

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

Interim results from a Phase III trial showed the combo benefited HER2-positive metastatic breast cancer patients in the first-line setting.

Trastuzumab biosimilars saw significant market uptake in Japan after reimbursement incentives were implemented, but ...

These involved enlarged lymph nodes are an integral part of ovarian cancer and, therefore, they should be removed even after chemotherapy, he said. In India, ovarian cases are increasing day by ...

She underwent surgery to remove the tumour. Listen to Story Sharmila Tagore was diagnosed with stage zero lung cancer in 2023 Her cancer was detected early, no chemotherapy needed Sharmila spoke about ...